Copyright
©The Author(s) 2015.
World J Hepatol. Jun 28, 2015; 7(12): 1617-1631
Published online Jun 28, 2015. doi: 10.4254/wjh.v7.i12.1617
Published online Jun 28, 2015. doi: 10.4254/wjh.v7.i12.1617
Table 2 Risk factors associated with therapeutic response to first-generation direct acting antivirals in patients previously treated with pegylated interferon and ribavirin
SVR rates (%) | |||||
Boceprevir | Telaprevir | ||||
Predictive variables | PR48 | BOCRGT | BOCPR48 | PR48 | T12PR48 |
Previous relapser | 29 | 69 | 75 | 24 | 83 |
Previous partial-responder | 7 | 40 | 52 | 15 | 59 |
Previous null responder | 5 | 29 | |||
Mild-moderate fibrosis | 23 | 63 | 68 | 16 | 76 |
Advanced fibrosis | 13 | 44 | 68 | 11 | 49 |
Black race | 8 | 61 | 63 | 10 | 55 |
HCVRNA viral load > 800.000 IU/mL (baseline) | |||||
IL28B C/C | 46 | 79 | 77 | 29 | 79 |
Il28B C/T | 17 | 61 | 73 | 16 | 60 |
IL28B T/T | 50 | 55 | 72 | 13 | 61 |
HCV genotype 1a | 24 | 5 | 61 | ||
HCV genotype 1b | 22 | 65 | 73 | ||
BMI < 25 | 20 | 6 | 68 | ||
BMI ≥ 30 | 11 | 56 | 65 | ||
Relapse | 15 | 59 | 54 |
- Citation: Cavalcante LN, Lyra AC. Predictive factors associated with hepatitis C antiviral therapy response. World J Hepatol 2015; 7(12): 1617-1631
- URL: https://www.wjgnet.com/1948-5182/full/v7/i12/1617.htm
- DOI: https://dx.doi.org/10.4254/wjh.v7.i12.1617